NCT03338790 2026-01-27
CheckMate 9KD
Bristol-Myers Squibb
Phase 2 Completed
Clinical Trials
10 trialsNCT02985957 2025-12-22
CheckMate 650
Bristol-Myers Squibb
Phase 2 Completed
NCT04100018 2025-06-12
CheckMate 7DX
Bristol-Myers Squibb
Phase 3 Completed
NCT03689699 2025-04-29
Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
Columbia University
Phase 1/2 Active not recruiting
NCT04159896 2024-07-16
ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT02933255 2024-05-31
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT03554317 2024-02-20
COMBAT-CRPC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02601014 2022-02-03
STARVE-PC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03572478 2021-03-09
Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer
University of Chicago
Phase 1/2 Terminated
NCT00441337 2015-02-20
MDX1106-01
Bristol-Myers Squibb
Phase 1 Completed